Searches , social queries for TRILACICLIB

Search references for TRILACICLIB. Phrases containing TRILACICLIB

See searches and references containing TRILACICLIB!

Searches containing TRILACICLIB

TRILACICLIB

  • Trilaciclib
  • Chemical compound

    Trilaciclib, sold under the brand name Cosela, is a medication used to reduce the frequency of chemotherapy-induced bone marrow suppression. The most

    Trilaciclib

    Trilaciclib

    Trilaciclib

  • G1 Therapeutics
  • Pharmaceutical company

    announced that Pharmacosmos had completed its purchase of G1 Therapeutics. Trilaciclib, a small molecule CDK4/6 inhibitor, is a first-in-class, FDA-designated

    G1 Therapeutics

    G1 Therapeutics

    G1_Therapeutics

  • Boehringer Ingelheim
  • German pharmaceutical company

    Boehringer and G1 Therapeutics announced a co-promotion agreement for trilaciclib (Cosela), a CDK4/6 inhibitor designed to prevent chemotherapy-induced

    Boehringer Ingelheim

    Boehringer Ingelheim

    Boehringer_Ingelheim

  • Small-cell carcinoma
  • Type of malignant cancer

    Grants Priority Review to Trilaciclib to Treat Patients with SCLC". Cancer Network. 17 August 2020. Retrieved 2020-12-04. "Trilaciclib | intravenous CDK4/6

    Small-cell carcinoma

    Small-cell carcinoma

    Small-cell_carcinoma

  • CDK inhibitor
  • Any chemical that inhibits the function of CDKs

    been FDA approved for mediating chemotherapy-induced side effects. 4. Trilaciclib (V03AF12, trade name Cosela) was approved in February 2021 to reduce

    CDK inhibitor

    CDK_inhibitor

  • Palbociclib
  • Medication for HR+ HER2– breast cancer

    Cyclin D3/CDK6 activity. G1 Therapeutics also has a CDK4/6 inhibitor, trilaciclib, which is up for FDA approval (target decision date of February 15, 2021)

    Palbociclib

    Palbociclib

    Palbociclib

  • Neutropenia
  • Abnormally low concentration of neutrophils (a type of white blood cell) in the blood

    trial data analysed results in a way that disfavoured amphotericin B. Trilaciclib, a CDK4/6 inhibitor, administered approximately thirty minutes before

    Neutropenia

    Neutropenia

    Neutropenia

  • Chemotherapy
  • Treatment of cancer using drugs that inhibit cell division or kill cells

    counteract depression of the immune system in people undergoing chemotherapy. Trilaciclib is an inhibitor of cyclin-dependent kinase 4/6 approved for the prevention

    Chemotherapy

    Chemotherapy

    Chemotherapy

  • Cyclin-dependent kinase
  • Class of enzymes

    HR+/HER2- breast cancer patients, including patients with brain metastases. Trilaciclib is used to decrease myelosuppression associated with chemotherapy with

    Cyclin-dependent kinase

    Cyclin-dependent kinase

    Cyclin-dependent_kinase

  • ATC code V03
  • Pharmaceutical drug classification

    Glucarpidase V03AF10 Sodium levofolinate V03AF11 Arginine and lysine V03AF12 Trilaciclib V03AG01 Sodium cellulose phosphate V03AG05 Sodium phosphate V03AH01 Diazoxide

    ATC code V03

    ATC_code_V03

  • Bone marrow suppression
  • Medical condition

    as a treatment of chemotherapy-induced myelosuppression/Neutropenia. Trilaciclib (COSELA), a CDK4/6 inhibitor, is administered before chemotherapy in

    Bone marrow suppression

    Bone_marrow_suppression

  • Elranatamab
  • Medication

    Vismodegib CDK inhibitors Abemaciclib Dalpiciclib Palbociclib Ribociclib Trilaciclib KRAS inhibitors Adagrasib Sotorasib Pi3K inhibitors Alpelisib Copanlisib

    Elranatamab

    Elranatamab

  • Zilurgisertib
  • Medication

    Vismodegib CDK inhibitors Abemaciclib Dalpiciclib Palbociclib Ribociclib Trilaciclib KRAS inhibitors Adagrasib Sotorasib Pi3K inhibitors Alpelisib Copanlisib

    Zilurgisertib

    Zilurgisertib

    Zilurgisertib

  • Metastatic breast cancer
  • Type of spreading cancer

    inhibitors like palbociclib, ribociclib, abemaciclib, dalpiciclib, and trilaciclib are used to treat HR+/HER- breast cancers, often in combination with

    Metastatic breast cancer

    Metastatic breast cancer

    Metastatic_breast_cancer

  • List of drugs granted breakthrough therapy designation
  • Evinacumab Regeneron Pharmaceuticals homozygous familial hypercholesterolemia Trilaciclib G1 Therapeutics myelosuppression, when administered prior to a platinum/etoposide

    List of drugs granted breakthrough therapy designation

    List_of_drugs_granted_breakthrough_therapy_designation

  • Mosunetuzumab
  • Monoclonal antibody

    Vismodegib CDK inhibitors Abemaciclib Dalpiciclib Palbociclib Ribociclib Trilaciclib KRAS inhibitors Adagrasib Sotorasib Pi3K inhibitors Alpelisib Copanlisib

    Mosunetuzumab

    Mosunetuzumab

Searches for online references containing TRILACICLIB

TRILACICLIB

Search references containing TRILACICLIB

TRILACICLIB

Search queries for Facebook and twitter posts, hashtags with TRILACICLIB

TRILACICLIB

Follow users with usernames @TRILACICLIB or posting hashtags containing #TRILACICLIB

TRILACICLIB

Online names & meanings

Search queries for Facebook and twitter users, user names, hashtags with TRILACICLIB

TRILACICLIB

Top search, Social media, medium, facebook & news articles containing TRILACICLIB

TRILACICLIB

Searches for Acronyms & meanings containing TRILACICLIB

TRILACICLIB

Searches, Indeed job searches and job offers containing TRILACICLIB

Other words and meanings similar to

TRILACICLIB

Search in online dictionary sources & meanings containing TRILACICLIB

TRILACICLIB